The association of plasma connective tissue growth factor levels with left ventricular diastolic dysfunction in

Huan Li1,2, Yahui Ren3, Linfang Wang4

  • 1Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in Endocrinology
|February 20, 2024
PubMed

Insights

Elevated connective tissue growth factor (CTGF) levels are linked to left ventricular (LV) diastolic dysfunction in hyperthyroid patients. Plasma CTGF may serve as an auxiliary biomarker for diagnosing this condition.

Area of Science:

  • Cardiology
  • Biomarkers
  • Thyroidology

Background:

  • Left ventricular (LV) diastolic dysfunction predicts cardiovascular events.
  • Early detection and management are crucial for improving outcomes.
  • Current biomarkers for assessing LV diastolic dysfunction risk are limited.

Purpose of the Study:

  • Investigate the association between plasma connective tissue growth factor (CTGF) levels and the risk of LV diastolic dysfunction.
  • Evaluate the effectiveness of plasma CTGF as a diagnostic marker for LV diastolic dysfunction.

Main Methods:

  • Included 169 patients with overt hyperthyroidism.
  • Assessed LV diastolic function and categorized patients into normal and dysfunction groups.
  • Analyzed clinical, biochemical, thyroid, and echocardiographic parameters, including plasma CTGF levels.

Main Results:

  • Patients with LV diastolic dysfunction exhibited higher age, BMI, and incidences of hypertension, along with lower heart rate, serum albumin, and eGFR.
  • Plasma CTGF levels were significantly higher in the LV diastolic dysfunction group (8.290 ng/ml vs. 7.026 ng/ml).
  • Higher CTGF quartiles correlated with increased odds of LV diastolic dysfunction, with an AUC of 0.659 for plasma CTGF.

Conclusions:

  • Circulating plasma CTGF levels are significantly elevated in patients with LV diastolic dysfunction.
  • Plasma CTGF is identified as an independent risk factor for LV diastolic dysfunction.
  • Plasma CTGF may offer auxiliary diagnostic value for LV diastolic dysfunction in hyperthyroid patients, potentially outperforming serum BNP.
Abstract

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92